Amyloidosis, Hereditary Clinical Trial
Official title:
Expanded Access Protocol of Patisiran for Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR Amyloidosis) With Polyneuropathy
The purpose of this study is to provide expanded access of patisiran to patients with hereditary transthyretin-mediated amyloidosis (hATTR).
Choosing to participate in an expanded access program is an important personal decision. Talk with your doctor and family members or friends about deciding to join a research study. To learn more about this study, please have your doctor contact the study research staff using the Contacts provided. For general information, see the links provided in More Information. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05974644 -
Southeastern ATTR Amyloidosis Consortium: SEATTRAC Family Registry
|
||
| Recruiting |
NCT05879874 -
Prospective Evaluation of NfL as a Biomarker in ATTRv
|
||
| Recruiting |
NCT05489549 -
Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers
|
||
| Completed |
NCT01960348 -
APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis
|
Phase 3 | |
| Active, not recruiting |
NCT03759379 -
HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
|
Phase 3 | |
| Completed |
NCT02319005 -
ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
|
Phase 3 | |
| Recruiting |
NCT05873868 -
Myocardial Effects in Patients With ATTRv With Polyneuropathy Treated With Patisiran or Vutrisiran
|
||
| Approved for marketing |
NCT03400098 -
ATTR Expanded Access Program (EAP) by Ionis
|